Vivan Therapeutics said it has secured all regulatory approvals needed to launch a clinical registration study of its TuMatch software at Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi.
The prospective trial will assess TuMatch, described by the company as a clinical decision support tool, in colorectal cancer patients. The study will be led by Prof. Humaid Al Shamsi, with a minimum of 10 patients enrolled at the Abu Dhabi site.
Beyond tracking clinical outcomes, the trial has been set up to gather health economics and value based care data. Vivan said this evidence is meant to feed into reimbursement talks with payers and to shape how AI enabled decision support gets taken up across the UAE health system. The company called the approval one of the first clearances of its kind issued in the Emirate for software of this class in oncology.
According to Vivan, TuMatch works by comparing a patient’s tumour genomic profile against its own drug response dataset, built using an in vivo Drosophila avatar screening method developed alongside Mount Sinai Medical Center, combined with published clinical findings. This produces a ranked list of treatment options for the oncologist, intended for patients who have run out of, or are unlikely to respond to, standard care.
Treatment gap
Dr Nahuel Villegas, chief scientific officer of Vivan Therapeutics, said: “Colorectal cancer is notoriously hard to treat, and particularly challenging for patients with activating KRAS mutations, who often have no effective standard-of-care options left. Our technology brings an ultra-personalised, genomics-matched approach into the clinic, giving each patient a tailored path built on their own tumour biology, and a real shot at a better outcome.”
Al Shamsi, chief executive of Burjeel Cancer Institute, said: “At Burjeel, we are committed to bringing innovative technologies and advanced decision-support tools to the UAE that can help physicians identify new possibilities and guide more personalized treatment strategies.”
Vivan noted that colorectal cancer ranks among the most frequently diagnosed cancers in the UAE, often appearing in younger patients or at a later stage than seen in Western populations.
Wider programme
The company said the Abu Dhabi trial sits within a larger clinical effort that will extend to a separate multicentre study covering pancreatic and other gastrointestinal cancers, with locations across Europe and the GCC. Results from this wider body of work are expected to feed into Vivan’s applications for a CE mark and FDA clearance for TuMatch.
Vivan is a member of Hub71, Abu Dhabi’s tech ecosystem, which it said helps startups gain access to strategic partners, capital and international markets. The company set up its regional entity in Abu Dhabi Global Market in 2025 and runs operations spanning the UK, USA, UAE and China.
The photo above was issued by Vivan Therapeutics with the announcement.